Author(s): Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, , Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H,
Abstract Share this page
Abstract Defective homologous recombination (HR) DNA repair imposed by BRCA1 or BRCA2 deficiency sensitizes cells to poly (ADP-ribose) polymerase (PARP)-1 inhibition and is currently exploited in clinical treatment of HR-deficient tumors. Here we show that mild hyperthermia (41-42.5 °C) induces degradation of BRCA2 and inhibits HR. We demonstrate that hyperthermia can be used to sensitize innately HR-proficient tumor cells to PARP-1 inhibitors and that this effect can be enhanced by heat shock protein inhibition. Our results, obtained from cell lines and in vivo tumor models, enable the design of unique therapeutic strategies involving localized on-demand induction of HR deficiency, an approach that we term induced synthetic lethality.
This article was published in Proc Natl Acad Sci U S A
and referenced in Journal of Cancer Science & Therapy